Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Dual functionality of β-tryptase protomers as both proteases and cofactors in the active tetramer.

Maun HR, Liu PS, Franke Y, Eigenbrot C, Forrest WF, Schwartz LB, Lazarus RA.

J Biol Chem. 2018 Jun 22;293(25):9614-9628. doi: 10.1074/jbc.M117.812016. Epub 2018 Apr 16.

PMID:
29661938
2.

Taming hyperactive hDNase I: Stable inducible expression of a hyperactive salt- and actin-resistant variant of human deoxyribonuclease I in CHO cells.

Lam C, Santell L, Wilson B, Yim M, Louie S, Tang D, Shaw D, Chan P, Lazarus RA, Snedecor B, Misaghi S.

Biotechnol Prog. 2017 Mar;33(2):523-533. doi: 10.1002/btpr.2439. Epub 2017 Feb 6.

PMID:
28127892
3.

Mining ancient proteins for next-generation drugs.

Lazarus RA, Scheiflinger F.

Nat Biotechnol. 2017 Jan 10;35(1):28-29. doi: 10.1038/nbt.3762. No abstract available.

PMID:
28072785
4.

An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides.

Landgraf KE, Steffek M, Quan C, Tom J, Yu C, Santell L, Maun HR, Eigenbrot C, Lazarus RA.

Nat Chem Biol. 2014 Jul;10(7):567-73. doi: 10.1038/nchembio.1533. Epub 2014 May 25.

PMID:
24859116
5.

Functional consequences of the macrophage stimulating protein 689C inflammatory bowel disease risk allele.

Kauder SE, Santell L, Mai E, Wright LY, Luis E, N'Diaye EN, Lutman J, Ratti N, Sa SM, Maun HR, Stefanich E, Gonzalez LC, Graham RR, Diehl L, Faubion WA Jr, Keir ME, Young J, Chaudhuri A, Lazarus RA, Egen JG.

PLoS One. 2013 Dec 23;8(12):e83958. doi: 10.1371/journal.pone.0083958. eCollection 2013.

6.

Allosteric inhibition of BACE1 by an exosite-binding antibody.

Wang W, Liu Y, Lazarus RA.

Curr Opin Struct Biol. 2013 Dec;23(6):797-805. doi: 10.1016/j.sbi.2013.08.001. Epub 2013 Aug 30. Review.

PMID:
23998983
7.

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.

Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, Santell L, Zhang YW, Su Y, Kaufman DW, Billeci KL, Mai E, Moffat B, Lim A, Duenas ET, Phillips HS, Xiang H, Young JC, Vande Woude GF, Dennis MS, Reilly DE, Schwall RH, Starovasnik MA, Lazarus RA, Yansura DG.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. doi: 10.1073/pnas.1302725110. Epub 2013 Jul 23.

8.

The structure of human DNase I bound to magnesium and phosphate ions points to a catalytic mechanism common to members of the DNase I-like superfamily.

Parsiegla G, Noguere C, Santell L, Lazarus RA, Bourne Y.

Biochemistry. 2012 Dec 21;51(51):10250-8. doi: 10.1021/bi300873f. Epub 2012 Dec 13.

PMID:
23215638
9.

Proteolytic activation of pro-macrophage-stimulating protein by hepsin.

Ganesan R, Kolumam GA, Lin SJ, Xie MH, Santell L, Wu TD, Lazarus RA, Chaudhuri A, Kirchhofer D.

Mol Cancer Res. 2011 Sep;9(9):1175-86. doi: 10.1158/1541-7786.MCR-11-0004. Epub 2011 Aug 29.

10.

A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.

Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, Peng K, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W, Wu Y, Tessier-Lavigne M, Watts RJ.

Sci Transl Med. 2011 May 25;3(84):84ra43. doi: 10.1126/scitranslmed.3002254.

11.

Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling.

Landgraf KE, Santell L, Billeci KL, Quan C, Young JC, Maun HR, Kirchhofer D, Lazarus RA.

J Biol Chem. 2010 Dec 17;285(51):40362-72. doi: 10.1074/jbc.M110.179721. Epub 2010 Oct 11.

12.

Interactions between Hedgehog proteins and their binding partners come into view.

Beachy PA, Hymowitz SG, Lazarus RA, Leahy DJ, Siebold C.

Genes Dev. 2010 Sep 15;24(18):2001-12. doi: 10.1101/gad.1951710. Review.

13.

Pseudo-active sites of protease domains: HGF/Met and Sonic hedgehog signaling in cancer.

Maun HR, Kirchhofer D, Lazarus RA.

Biol Chem. 2010 Aug;391(8):881-92. doi: 10.1515/BC.2010.098. Review.

PMID:
20536384
14.

Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site.

Maun HR, Wen X, Lingel A, de Sauvage FJ, Lazarus RA, Scales SJ, Hymowitz SG.

J Biol Chem. 2010 Aug 20;285(34):26570-80. doi: 10.1074/jbc.M110.112284. Epub 2010 May 26.

15.

Bi-directional SIFT predicts a subset of activating mutations.

Lee W, Zhang Y, Mukhyala K, Lazarus RA, Zhang Z.

PLoS One. 2009 Dec 14;4(12):e8311. doi: 10.1371/journal.pone.0008311.

16.

The structure of SHH in complex with HHIP reveals a recognition role for the Shh pseudo active site in signaling.

Bosanac I, Maun HR, Scales SJ, Wen X, Lingel A, Bazan JF, de Sauvage FJ, Hymowitz SG, Lazarus RA.

Nat Struct Mol Biol. 2009 Jul;16(7):691-7. doi: 10.1038/nsmb.1632. Epub 2009 Jun 28.

PMID:
19561609
17.

Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide.

Tam EM, Runyon ST, Santell L, Quan C, Yao X, Kirchhofer D, Skelton NJ, Lazarus RA.

J Mol Biol. 2009 Jan 9;385(1):79-90. doi: 10.1016/j.jmb.2008.09.091. Epub 2008 Oct 15.

PMID:
18973760
18.

Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.

Kirchhofer D, Lipari MT, Santell L, Billeci KL, Maun HR, Sandoval WN, Moran P, Ridgway J, Eigenbrot C, Lazarus RA.

Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5306-11. Epub 2007 Mar 19.

19.

The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus.

Manderson AP, Carlucci F, Lachmann PJ, Lazarus RA, Festenstein RJ, Cook HT, Walport MJ, Botto M.

Arthritis Res Ther. 2006;8(3):R68. Epub 2006 Apr 10.

20.

Disulfide locked variants of factor VIIa with a restricted beta-strand conformation have enhanced enzymatic activity.

Maun HR, Eigenbrot C, Raab H, Arnott D, Phu L, Bullens S, Lazarus RA.

Protein Sci. 2005 May;14(5):1171-80.

21.

Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.

Shia S, Stamos J, Kirchhofer D, Fan B, Wu J, Corpuz RT, Santell L, Lazarus RA, Eigenbrot C.

J Mol Biol. 2005 Mar 11;346(5):1335-49. Epub 2005 Jan 28.

PMID:
15713485
22.

Inhibitors of Tissue Factor. Factor VIIa for anticoagulant therapy.

Lazarus RA, Olivero AG, Eigenbrot C, Kirchhofer D.

Curr Med Chem. 2004 Sep;11(17):2275-90. Review.

PMID:
15379712
23.

Suppressor of fused regulates Gli activity through a dual binding mechanism.

Merchant M, Vajdos FF, Ultsch M, Maun HR, Wendt U, Cannon J, Desmarais W, Lazarus RA, de Vos AM, de Sauvage FJ.

Mol Cell Biol. 2004 Oct;24(19):8627-41.

24.

Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.

Kirchhofer D, Yao X, Peek M, Eigenbrot C, Lipari MT, Billeci KL, Maun HR, Moran P, Santell L, Wiesmann C, Lazarus RA.

J Biol Chem. 2004 Sep 17;279(38):39915-24. Epub 2004 Jun 24.

25.

Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor.

Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C.

EMBO J. 2004 Jun 16;23(12):2325-35. Epub 2004 May 27.

26.

Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.

Kirchhofer D, Peek M, Li W, Stamos J, Eigenbrot C, Kadkhodayan S, Elliott JM, Corpuz RT, Lazarus RA, Moran P.

J Biol Chem. 2003 Sep 19;278(38):36341-9. Epub 2003 Jun 18.

27.

Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage.

Maun HR, Eigenbrot C, Lazarus RA.

J Biol Chem. 2003 Jun 13;278(24):21823-30. Epub 2003 Mar 25.

28.

Albumin affinity tags increase peptide half-life in vivo.

Koehler MF, Zobel K, Beresini MH, Caris LD, Combs D, Paasch BD, Lazarus RA.

Bioorg Med Chem Lett. 2002 Oct 21;12(20):2883-6.

PMID:
12270169
29.

Fusion of two distinct peptide exosite inhibitors of Factor VIIa.

Roberge M, Peek M, Kirchhofer D, Dennis MS, Lazarus RA.

Biochem J. 2002 Apr 15;363(Pt 2):387-93.

30.

A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors.

Roberge M, Santell L, Dennis MS, Eigenbrot C, Dwyer MA, Lazarus RA.

Biochemistry. 2001 Aug 14;40(32):9522-31.

PMID:
11583151
31.

Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa.

Dennis MS, Roberge M, Quan C, Lazarus RA.

Biochemistry. 2001 Aug 14;40(32):9513-21.

PMID:
11583150
32.

The factor VII zymogen structure reveals reregistration of beta strands during activation.

Eigenbrot C, Kirchhofer D, Dennis MS, Santell L, Lazarus RA, Stamos J, Ultsch MH.

Structure. 2001 Jul 3;9(7):627-36.

33.

Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.

Zahm JM, Debordeaux C, Maurer C, Hubert D, Dusser D, Bonnet N, Lazarus RA, Puchelle E.

Am J Respir Crit Care Med. 2001 Apr;163(5):1153-7.

PMID:
11316652
34.

Assays for human DNase I activity in biological matrices.

Sinicropi DV, Lazarus RA.

Methods Mol Biol. 2001;160:325-33. Review. No abstract available.

PMID:
11265293
35.

Engineered properties and assays for human DNase I mutants.

Pan CQ, Sinicropi DV, Lazarus RA.

Methods Mol Biol. 2001;160:309-21. Review. No abstract available.

PMID:
11265292
36.

Recombinant decorsin: dynamics of the RGD recognition site.

Krezel AM, Ulmer JS, Wagner G, Lazarus RA.

Protein Sci. 2000 Aug;9(8):1428-38.

37.

Peptide exosite inhibitors of factor VIIa as anticoagulants.

Dennis MS, Eigenbrot C, Skelton NJ, Ultsch MH, Santell L, Dwyer MA, O'Connell MP, Lazarus RA.

Nature. 2000 Mar 30;404(6777):465-70.

PMID:
10761907
38.

Ca2+-dependent activity of human DNase I and its hyperactive variants.

Pan CQ, Lazarus RA.

Protein Sci. 1999 Sep;8(9):1780-8.

39.

Expression and characterization of a DNase I-Fc fusion enzyme.

Dwyer MA, Huang AJ, Pan CQ, Lazarus RA.

J Biol Chem. 1999 Apr 2;274(14):9738-43.

40.

Cloning and characterization of an actin-resistant DNase I-like endonuclease secreted by macrophages.

Baron WF, Pan CQ, Spencer SA, Ryan AM, Lazarus RA, Baker KP.

Gene. 1998 Jul 30;215(2):291-301.

PMID:
9714828
41.

Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus.

Pan CQ, Dodge TH, Baker DL, Prince WS, Sinicropi DV, Lazarus RA.

J Biol Chem. 1998 Jul 17;273(29):18374-81.

44.
45.

Potent bifunctional anticoagulants: Kunitz domain-tissue factor fusion proteins.

Lee GF, Lazarus RA, Kelley RF.

Biochemistry. 1997 May 13;36(19):5607-11.

PMID:
9153400
46.

Engineering actin-resistant human DNase I for treatment of cystic fibrosis.

Ulmer JS, Herzka A, Toy KJ, Baker DL, Dodge AH, Sinicropi D, Shak S, Lazarus RA.

Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8225-9.

47.

A comparison of the effect of decorsin and two disintegrins, albolabrin and eristostatin, on platelet function.

McLane MA, Gabbeta J, Rao AK, Beviglia L, Lazarus RA, Niewiarowski S.

Thromb Haemost. 1995 Nov;74(5):1316-22.

PMID:
8607116
48.

Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display.

Dennis MS, Herzka A, Lazarus RA.

J Biol Chem. 1995 Oct 27;270(43):25411-7.

49.
50.

Ecotin is a potent inhibitor of the contact system proteases factor XIIa and plasma kallikrein.

Ulmer JS, Lindquist RN, Dennis MS, Lazarus RA.

FEBS Lett. 1995 May 29;365(2-3):159-63.

Supplemental Content

Loading ...
Support Center